Q3 FY26 results: revenue up 39% YoY at Rs 6,116 Mn

Revenue growth above 20%Profit growth above 25%Exceptional itemResults View source PDF Explain this filing

ASTRAZEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.9%Reaction day

₹9090.00

prior close

₹8790.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.5%-2.4% vs market

Pharmaceuticals peers, median of 157sector-0.6%-2.2% vs sector

On the reaction day the stock moved 2.4 pts less than Nifty Microcap 250 and 2.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.8

10m

-1.5

15m

-1.5

30m

-1.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.9-0.5-2.4-0.6-2.2

Next day

-2.5-2.0-0.5-1.4-1.1

-2.0-2.7+0.7-2.1+0.2

-2.0-1.7-0.3-1.6-0.4

-2.6-1.4-1.2-1.6-1.0

-2.1-2.8+0.7-2.5+0.4

-3.0-2.8-0.1-2.9-0.1

15d

-4.6-8.4+3.8-6.5+1.9

-5.4-9.1+3.7-6.6+1.3

-2.6-4.0+1.4-3.5+0.8

-7.6+2.6-10.2+0.9-8.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Revenue from operations grew 39% YoY to Rs 6,115.7 Mn in Q3 FY26, with nine-month revenue at Rs 16,969.7 Mn, up 37%. Q3 profit after tax stood at Rs 325.9 Mn versus Rs 308.5 Mn a year ago. Nine-month profit after tax surged to Rs 1,426.4 Mn from Rs 574.9 Mn. The company secured 8 new regulatory approvals in the nine months across Oncology, Biopharm and Rare Disease. Bangalore manufacturing site operations have ceased and the site is being sold, with related exceptional items included in the results. A provision of Rs 278.3 Mn was taken for past service cost on gratuity under new Labour Codes.

Likely market impact

Strong revenue growth and regulatory momentum are positive for shareholders. Manufacturing site closure continues to add near-term costs and exceptional items.